EDIL3 and rheumatoid arthritis: This suggests that treatment with CDK9 inhibitors leads to maintained Del-1 expression in endothelial cells, which might contribute to protection against RA by limiting LFA-1-mediated neutrophil trafficking to inflamed tissues.